

EUROPEAN COMMISSION HEALTH AND FOOD SAFETY DIRECTORATE-GENERAL

Health systems, medical products and innovation Performance of national health systems

Expert Panel on Effective Ways of Investing in Health

2nd Working Group meeting on Innovative payment models for high-cost innovative medicines

F101 01/89 Monday 20 March 2017, 15:30 – 18:00 h CET

MINUTES

| 1. | Participants | | |
|----|------------------|---|--|
| | 1.1. Members | Walter Ricciardi (WR) Pedro Barros (PB) Aleš Bourek (AB) Werner Brouwer (WB) Lasse Lehtonen (LL) Martin McKee (MMK) Claudia Wild (CW) | Chair Rapporteur Apologies By phone |
| | 1.2. Secretariat | Dimitrios Florinis (DM) Efrossyni Prinea (EP) Päivi Kontinen (PK) | |

2. Welcome and apologies

The Chair opened the meeting and welcomed the participants. Apologies were received from Aleš Bourek.

3. Mandate

Summary of work so far

The rapporteur outlined the work done so far as a result of the previous discussions. He then explained the draft layout of the opinion, which currently includes five main headings setting up concepts for discussion:

The challenges of health systems; the challenges for discussion under the mandate; the principles to face the challenges; the instruments to face the challenge; and the views of the Panel.

The WG discussed the challenges posed by the mandate and the principles to face them. Some of the main points were the role of directing R&D, the role of affordability to health systems and to patients, the role of intergenerational

transfers, how to balance objectives and different instruments, how to avoid intellectual capture by healthcare providers and what the objectives are.

A discussion on current and new instruments to use to face the challenge followed. Pricing and innovation procurement initiatives were also discussed. Competition and market power issues as well as bargaining as price setting were touched upon.

In addition, structured international cooperation leading to better use of products and how to split the cost of innovation between countries was raised. Also, the possible need for adaptive pathways and taking risks for speedier access to medicines was discussed.

It was agreed to refer to the Opinions from the previous Expert Panel on Health and to use them as a reference.

Action points:

1. The WG members to send contributions to the rapporteur by 12 April.

2. The rapporteur will prepare a first draft by 20 April.

3.1. Practical arrangements

An audio conference is scheduled for 4 May in the afternoon.

The next WG meeting will take place in Brussels on 17 May.